RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 30 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 30

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
  2. Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
  3. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  4. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  5. Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
  6. Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
  7. Study siteCancer Hospital CAMS – Shenzhen中国医学科学院肿瘤医院深圳医院ShenzhenHospital page
  8. Study siteCancer Hospital, Shandong First Medical University山东省肿瘤医院JinanHospital page
  9. Study siteFirst Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院BeijingHospital page
  10. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  11. Study siteFirst Affiliated Hospital of Shandong First Medical University山东第一医科大学第一附属医院(山东省千佛山医院)JinanHospital page
  12. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  13. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  14. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  15. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  16. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  17. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  18. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  19. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  20. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  21. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  22. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  23. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  24. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  25. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  26. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
  27. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  28. Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
  29. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  30. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06809764, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06809764, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

The key inclusion criteria for this study are:

  • Age ≥18 years at signing informed consent form (ICF).
  • Pathologically documented unresectable and/or metastatic non-squamous NSCLC.
  • Documented any known activating HER2 mutation.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
  • Patients who receive T-DXd based on physicians' discretion (Newly received or just have started the first dose no longer than 2 months before enrollment).

The key exclusion criteria for this study are:

  • Previously treated with HER2-targeted/directed therapies, including:
  • tyrosine kinase inhibitors [TKIs] targeting HER2 mutations, except for pan-HER class TKIs.
  • an ADC, containing a chemotherapeutic agent targeting topoisomerase I
  • Has spinal cord compression or clinically active CNS metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
  • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension active bleeding diatheses, etc.

Quoted from ClinicalTrials.gov, NCT06809764, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06809764, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06809764